Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill, Daniel J. Drucker
Endocrine Reviews (2014) Vol. 35, Iss. 6, pp. 992-1019
Open Access | Times Cited: 528

Showing 26-50 of 528 citing articles:

Bioavailability of Hesperidin and Its Aglycone Hesperetin—Compounds Found in Citrus Fruits as a Parameter Conditioning the Pro-Health Potential (Neuroprotective and Antidiabetic Activity)—Mini-Review
Kamil Wdowiak, Jarosław Walkowiak, Robert Pietrzak, et al.
Nutrients (2022) Vol. 14, Iss. 13, pp. 2647-2647
Open Access | Times Cited: 69
DPP4 in Cardiometabolic Disease
Jixin Zhong, Andrei Maiseyeu, Stephen N. Davis, et al.
Circulation Research (2015) Vol. 116, Iss. 8, pp. 1491-1504
Open Access | Times Cited: 166
Adipose Organ Development and Remodeling
Saverio Cinti
Comprehensive physiology (2018), pp. 1357-1431
Open Access | Times Cited: 155
Precision medicine in the management of type 2 diabetes
Anna L. Gloyn, Daniel J. Drucker
The Lancet Diabetes & Endocrinology (2018) Vol. 6, Iss. 11, pp. 891-900
Open Access | Times Cited: 146
TCF1 links GIPR signaling to the control of beta cell function and survival
Jonathan E. Campbell, John R. Ussher, Erin E. Mulvihill, et al.
Nature Medicine (2015) Vol. 22, Iss. 1, pp. 84-90
Closed Access | Times Cited: 129
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
Sophie Hallakou‐Bozec, Guillaume Vial, Micheline Kergoat, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 664-673
Open Access | Times Cited: 125
Long noncoding RNA CA7-4 promotes autophagy and apoptosis via sponging MIR877-3P and MIR5680 in high glucose-induced vascular endothelial cells
Xuan Zhao, Le Su, Xiaoying He, et al.
Autophagy (2019) Vol. 16, Iss. 1, pp. 70-85
Open Access | Times Cited: 121
The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling
J. Abraham Domínguez‐Ávila, Joaquín Rodrigo García, Gustavo A. González‐Aguilar, et al.
Molecules (2017) Vol. 22, Iss. 6, pp. 903-903
Open Access | Times Cited: 120
Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
Elodie M. Varin, Erin E. Mulvihill, Jacqueline L. Beaudry, et al.
Cell Metabolism (2018) Vol. 29, Iss. 2, pp. 320-334.e5
Open Access | Times Cited: 119
GLP-1 and Amylin in the Treatment of Obesity
Tina Jorsal, Joergen Rungby, Filip K. Knop, et al.
Current Diabetes Reports (2015) Vol. 16, Iss. 1
Closed Access | Times Cited: 116
The safety of gliptins : updated data in 2018
André Scheen
Expert Opinion on Drug Safety (2018) Vol. 17, Iss. 4, pp. 387-405
Closed Access | Times Cited: 116
Impact of Diabetes in Patients Diagnosed With COVID-19
Mohamed Abu‐Farha, Fahd Al‐Mulla, Thangavel Alphonse Thanaraj, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 107
Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis
Alina Soare, Hermina A. Györfi, Alexandru‐Emil Matei, et al.
Arthritis & Rheumatology (2019) Vol. 72, Iss. 1, pp. 137-149
Open Access | Times Cited: 104
Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era
Ammira Al‐Shabeeb Akil, Esraa Yassin, Aljazi Al-Maraghi, et al.
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 100
Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes
David Fitchett, Jacob A. Udell, Silvio E. Inzucchi
European Journal of Heart Failure (2016) Vol. 19, Iss. 1, pp. 43-53
Open Access | Times Cited: 97
Diabetes, hypertension, and chronic kidney disease progression: role of DPP4
Ravi Nistala, Virginia J. Savin
AJP Renal Physiology (2017) Vol. 312, Iss. 4, pp. F661-F670
Closed Access | Times Cited: 97
Do we know the true mechanism of action of the DPP‐4 inhibitors?
Emilie S. Andersen, Carolyn F. Deacon, Jens J. Holst
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 1, pp. 34-41
Closed Access | Times Cited: 95
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
Keizo Kanasaki
Clinical Science (2018) Vol. 132, Iss. 4, pp. 489-507
Open Access | Times Cited: 95
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?
Ricardo Godinho, Cristina Mega, Edite Teixeira‐Lemos, et al.
Journal of Diabetes Research (2015) Vol. 2015, pp. 1-28
Open Access | Times Cited: 93
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Alexei Kharitonenkov, Richard D. DiMarchi
Journal of Internal Medicine (2016) Vol. 281, Iss. 3, pp. 233-246
Open Access | Times Cited: 93
Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis
Erin E. Mulvihill, Elodie M. Varin, Bojana Gladanac, et al.
Cell Metabolism (2016) Vol. 25, Iss. 1, pp. 152-165
Open Access | Times Cited: 90
The Unique Metabolic Characteristics of Bone Marrow Adipose Tissue
Yujue Li, Yang Meng, Xijie Yu
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 89
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Jonathan E. Campbell
Molecular Metabolism (2020) Vol. 46, pp. 101139-101139
Open Access | Times Cited: 86
Diabetes and COVID-19: The past, the present, and the future
Raymond Pranata, Joshua Henrina, Wilson Matthew Raffaello, et al.
Metabolism (2021) Vol. 121, pp. 154814-154814
Open Access | Times Cited: 86

Scroll to top